Roche Receives FDA Approval for Viral Load Tests and Cobas 6800/8800 Systems
News Oct 18, 2015
The fully automated systems offer the fastest time to results, the highest throughput and the longest walk-away time available among automated molecular platforms, providing laboratories both improved operating efficiency and flexibility to adapt to changing testing needs. The new tests are the next generation of Roche’s viral load tests, which clinicians use to manage the treatment of patients chronically infected with hepatitis B or hepatitis C virus.
“These new systems will provide laboratories with solutions for routine molecular testing that offer excellent performance, unmatched flexibility and absolute automation,” said Roland Diggelmann, COO, Roche Diagnostics. “The cobas HBV and cobas HCV tests set new industry standards for viral load assays for the highly evolving hepatitis treatment regimens.”
In addition to the assays approved today, Roche currently has viral load tests under FDA review for HIV-1 and cytomegalovirus (CMV)*, which, when approved, will complete a comprehensive portfolio of viral load monitoring for the cobas 6800/8800 systems. Further menu expansion plans include qualitative tests for donor screening, women’s health and microbiology.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.